Close Menu

Breaking News

The ePlex SARS-CoV-2 Test is exclusively for use on the company's ePlex sample-to-answer system, which has a global installed base of more than 500 as of the end of 2019.

Researchers from the Human Genome Diversity Project discovered common genetic variation that is largely restricted to regions of Africa, Oceania, and the Americas.

Researchers used MRI and genetic data to uncover genetic loci that affect surface area and average thickness of the human cerebral cortex. 

The authors of the study noted that these genetic findings could guide better clinical decisions for patients and improve outcomes.

The company has also submitted its ANDiS automated nucleic acid extraction system and ANDiS SARS-CoV-2 RT-qPCR detection kit to the US FDA for Emergency Use Authorization.

The company has said it expects to be able to perform roughly 10,000 tests a day by the end of this week and roughly 20,000 tests per day by the end of March.

The company said its sales team will serve healthcare providers by telephone and online until it's safe to return to the field.

The Guangzhou, China-based startup has been developing a CRISPR-based diagnostic test for tuberculosis and raised $14 million in a Series A financing round last year.

The test will run on the m2000 RealTime molecular system, and the company said it will be shipping 150,000 tests immediately.

The test is the fourth COVID-19 molecular diagnostic to be awarded funding from BARDA. Others include Hologic, Qiagen, and DiaSorin Molecular.

The QiaStat-Dx Respiratory SARS-CoV-2 Panel can detect and differentiate SARS-CoV-2 and 21 other respiratory pathogens in symptomatic patients.

The Delaware jury said Oxford Nanopore had infringed three patents, but also found that they were invalid, mostly because they were not enabled.

The deal includes key testing services like Transplant's TruGraf blood test and Viracor's TRAC test, along with Viracor Eurofins' new SARS-CoV-2 test.

Previous studies that detected the presence of the N6-methyladenine bacterial DNA modification in mammalian cells were most likely contaminated.

The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.

Though it is unclear whether the virus became pathogenic before or after the jump from animals to humans, genomic features point to a natural source for the COVID-19 coronavirus.

The screen, which multiplexes Cas9 and Cas12a, could be used for functional analysis of large genomic regions in mammalian cells, the researchers said.

The test from Singapore-based Credo requires minimal training to run and can detect pathogens in 20 minutes, with about one minute of hands-on time.

The reimbursement contract provides about 9 million additional men access to the urine-based, genomic EPI test, Bio-Techne said.

The EUA is the fifth in less than a week from the FDA for assays to detect SARS-CoV-2 as testing capacity in the US continues to ramp up.

The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.

The RT-qPCR test was made available last week after validation in accordance with the US Food and Drug Administration's Emergency Use Authorization guidance.

North Dakota-based MedScan Laboratory will collect patient samples and extract RNA for Fulgent's new NGS-based clinical assay for SARS-CoV-2.

The joint submission of the coronavirus assay is part of a long-standing collaboration between the two firms to put BioGX assays on the BD Max system.

The testing products, developed by China-based 3D Medicines, have received CE marking and approval from the Chinese National Medical Products Administration, Todos said.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.